¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(1ÀÏÂ÷) : 2022-12-02

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(1ÀÏÂ÷) : 2022-12-02
±³À°ÀÏÀÚ : 2022-12-02
±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼­¿ï È£ÅÚ ±×·£µåȦ  
±³À°ÁÖÁ¦ : 2022 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ  
´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520  
À̸ÞÀÏ : retina@retina.or.kr      
±³À°Á¾·ù : ¾È°ú      
Âü¼®¿¹»óÀοø : 350¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 36ºÐ  
¼¼ºÎ¼ö°­·á : 100,000¿ø      
ºñ°í È¸ºñ³³ºÎ ȸ¿ø µî·Ïºñ ¸éÁ¦Àü°ø,ÀüÀÓÀÇ 8¸¸¿øÀü¹®ÀÇ 10¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:10~09:17 Incidence of Retinal Artery Occlusion and Related Mortality: Data from the Entire Korean Population between 2005 and 2018  È²´öÁø(Çѱæ¾È°úº´¿ø) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:17~09:24 Psoriasis increased risk for neovascular AMD and Retinal vein occlusion in Diabetic Patients : A nationwide population-based study  À̹̿¬(°¡Å縯´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:24~09:31 Sphingosine-1-phosphate expression in human epiretinal membranes  Àü¼ÒÈñ(Ä«À̾Ȱú) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:31~09:38 Update on Seoul Artificial Retina Project ¼­¿ïÀΰø¸Á¸· ¿¬±¸ÀÇ ÃÖ±Ù »óȲ  ¼­Á¾¸ð(¼­¿ï´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:38~09:45 Does the retina reflect past blood pressure conditions?  Á¶¹üÁÖ(ÇѸ²´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:45~09:52 Correlated activity in the degenerate retina inhibits focal response to electrical stimulation  ±¸¿ë¼÷(ÃæºÏ´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:00~10:09 ERM ¼ö¼ú Áß °©Àڱ⠹߻ýÇÑ eyeball collapse  Á¤¾Æ¸§(¿µ³²´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:09~10:18 Sticky silicone oil¿¡ ´ëóÇÏ´Â ¹ý  ÃÖÀº¿µ(¿¬¼¼´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:18~10:27 Chandelier-assisted scleral buckling for RRD patient with atopic dermatitis  °­¿ë±¸(°æºÏ´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:27~10:36 A case of vitrectomy using artificial cornea in a patient with total corneal opacity due to corneal ulcer  ±è·¡¿µ(°¡Å縯´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:36~10:45 Schlieren phenomenon in vitreomacular traction: is this subretinal fluid?  ¹®¿ë¼®(ÇѸ²´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:45~10:54 A case of a frustrating repair of the patient with suprachoroidal hemorrhage  ¾çÁö¸í(µ¿±¹´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 11:05~11:30 Molecular Mechanisms of Pathologic Retinal Angiogenesis  Leo A. Kim(Harvard Medical School) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 11:30~11:43 Bisretinoids: visual cycle adducts and implications for retinal diseases  ±èÇýÁø(°è¸í´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 11:43~11:56 Retinal degeneration by intraflagellar transport defects of photoreceptors  ÀÌÁØ¿±(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 11:56~12:09 Gene-edited human retinal organoid and mouse models to study inherited retinal diseases  ÀÌÁØ¿ø(¿¬¼¼´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 12:15~12:35 Unmet Needs in PCV & Brolucizumab Clinical Evidence in PCV  ±è¼ºÅÃ(Á¶¼±´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 12:35~12:55 Optimizing management using Brolucizumab in recalcitrant nAMD  ½ÅÁÖ¿µ(¼­¿ï´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 13:25~13:49 Using OCT to enhance the outcomes of ERM surgery  Stanley Chang(Columbia University) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 13:49~14:02 Before deciding to peel the membrane off the macula  À̽±Ô(¿¬¼¼´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 14:02~14:15 Special considerations in surgery for ERM: ILM tear  ¿©ÁØÇü(Áß¾Ó´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 14:45~14:52 Incidence and Clinical Course of Acute Endophthalmitis after Idiopathic Epiretinal Membrane Surgery with Microincision Vitrectomy  ±ÇÇÑÁ¶(ºÎ»ê´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 14:52~14:59 1Â÷ ¼ö¼ú·Î Æó¼âµÇÁö ¾ÊÀº ³­Ä¡¼º Ȳ¹Ý¿ø°ø¿¡¼­ ÀÚ°¡Ç÷¼ÒÆdzóÃà¾× ÁÖÀÔ¼úÀÇ À¯¿ë¼º  ³ªÈ£(°¡Å縯´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 14:59~15:06 Pearls and Pitfalls in ERM surgery with bare RNFL: Practical Tips to Minimize Retinal Damage  ¾çÁö¸í(µ¿±¹´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 15:06~15:13 Stress-free ILM flap technique  º¯¼®È£(¿¬¼¼´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 15:13~15:20 Topographic Assessment of Intraretinal Cyst Lesions and Its Prognostic Values in Idiopathic Epiretinal Membrane  º¯Àͼö(ºÎ»ê´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 15:20~15:27 ¾È±¸ Á¾¾çÀÇ »ý°Ë°ú Áø´Ü  ±è¹Î(¿¬¼¼´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 15:35~15:52 À¯¸®Ã¼¸Á¸·ÀÇ °¨¿°¼º Áúȯ¿¡¼­ vitreous base shaving - °¡´ÉÇÑ vitreous base±îÁö ±ú²ýÇÏ°Ô Á¦°ÅÇÑ´Ù/- Vitreous base¸¦ ¹«¸®Çؼ­ Á¦°ÅÇÏÁö ¾Ê´Â´Ù  Áö¿µ¼®,Ȳ´öÁø(Àü³²´ë,Çѱæ¾È°úº´¿ø) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 15:52~16:09 ¶ó´ÏºñÁÖ¸¿/¾ÖÇø®¹ö¼ÁÆ®¿¡ Ä¡·á ¹ÝÀÀÀÌ Á¦ÇÑÀûÀÎ neovascular AMDÀÇ Ä¡·á - °¡´ÉÇÑ ±âÁ¸ ¾àÁ¦¸¦ ÀÌ¿ëÇÏ¿© Ä¡·á¸¦ Áö¼ÓÇÑ´Ù/ - Àû±ØÀûÀ¸·Î ºê·Ñ·ç½ÃÁÖ¸¿ ±³Ã¼Åõ¿©¸¦ ½ÃÇàÇÑ´Ù  À±Ã¢±â,Á¶ÇÑÁÖ(¼­¿ï´ë,±è¾È°úº´¿ø) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 16:09~16:26 RVO¿¡¼­ÀÇ anti-VEGF Ä¡·á - As-needed ÁÖ»ç·Î ÃæºÐÇÏ´Ù/- Proactive Áֻ縦 Àû±ØÀûÀ¸·Î ½ÃÇàÇØ º¼ ¼ö ÀÖ´Ù  À̱âȲ,»ç°ø¹Î(¾ÆÁÖ´ë,¿µ³²´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 16:26~16:43 DME ¾ø´Â PDR¿¡¼­ PRP ½Ã anti-VEGF ÁÖ»çÀÇ ½Ã±â - PRP Àü¿¡ ¿¹¹æÀûÀ¸·Î ½ÃÇàÇÏ´Â °æ¿ìµµ ¸¹´Ù/- PRP ÈÄ DME°¡ ¹ß»ýÇÏ´Â °æ¿ì¿¡¸¸ ½ÃÇàÇÑ´Ù  ±èµ¿À±,±è¿ë±Ô(¼­¿ïž¾È°ú,ÇѸ²´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 16:50~16:57 The effect of nondamaging subthreshold laser therapy in patients with chronic central serous chorioretinopathy  ³ë¿µÁ¤(°¡Å縯´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 16:57~17:04 DeepPDT-Net: Predicting the Outcome of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Using Two-Stage Multimodal Transfer Learning  ÃÖÀº¿µ(¿¬¼¼´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:04~17:11 Clinical applications of metagenomic NGS in fungal endophthalmitis  ÀÌÁØ¿±(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:11~17:18 DNA methylome and somatic mutation profiles in the aged retina and choroid  ÁÖ±¤½Ä(¼­¿ï´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:18~17:25 Differences in the incidence of aflibercept-related sterile endophthalmitis according to types of disposable syringes used  ±èÁöÅÃ(Áß¾Ó´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:25~17:32 Molecular characteristics of uveal melanoma in Korean patients  À̽±Ô(¿¬¼¼´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:32~17:39 ºñÆÄ¿­¼º ³úµ¿¸Æ·ù Ä¡·á·Î ÄÚÀÏ»öÀü¼úÀ» ¹ÞÀº ÈÄ ¹ß»ýÇÏ´Â ¸Á¸·µ¿¸Æ/¼¼µ¿¸Æ Æó¼âÀÇ ºóµµ ¹× Ư¼º  ±è¿ëÁØ(¿¬¼¼´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:39~17:46 Screening Practices Associated with Late Diagnosis of Hydroxychloroquine Retinopathy: Hospital-based and Population-based studies  ¾È¼ºÁØ(ÇѾç´ë) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 18:00~18:20 10 years of EYLEA¢ç in Retina Society: unchanged positive long-term benefit-risk profile  ±èÀ±Àü(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 12-02 ±×·£µåȦ 18:20~18:40 Optimizing patient care with EYLEA¢ç : flexibility and beyond  Á¶ÇÑÁÖ(±è¾È°úº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(1ÀÏÂ÷) : 2022-12-02""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ÇѾç´ëÇб³±¸¸®º´¿ø ±¸¸®³²¾çÁÖ ¿Ü°ú °³¿øÀÇ ¿¬¼ö°­Á : 2022-12-02
´ÙÀ½±Û ¼­¿ï´ëÇб³ ¾î¸°À̺´¿ø ÁöÇÏ1Ãþ Á¦ÀÏÁ¦´çȦ ¹× CJȦ : 2022-12-02
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
135 °æ±â Á¦59ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ¼¼¹Ì³ª : 2018-08-26 0 1,844 2018-07-28
134 ¼­¿ï Á¦8ȸ »ï¼º¼­¿ïº´¿ø ¼Ò¾Æû¼Ò³â¼¾ÅÍ ½ÉÆ÷Áö¾ö(ÁÖÁ¦: ÈçÈ÷ ¸¸³ª°Ô µÇ´Â ¼Ò¾Æû¼Ò³â Áúȯ) : 2018-08-26 0 723 2018-07-28
133 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø Á¦9ȸ ¿¬¼¼ÀÇ´ë ¼Ò¾Æ°úÇб³½Ç, ¼Ò¾Æ¾Ë·¹¸£±âÈ£Èí±âÁúȯ ¿¬¼ö°­Á : 2018-08-26 0 395 2018-07-28
132 ¼­¿ï 2018 ´ëÇѼö¸éÇÐȸ ¿öÅ©¼¥ : 2018-08-26 0 482 2018-07-28
131 °æºÏ ´ëÇѼҾưúÇÐȸ ¼Ò¾Æû¼Ò³â°ú ¿Ü·¡¿¡¼­ Àû¿ë °¡´ÉÇÑ ÀÓ»óÁö½Ä : 2018-08-26 0 652 2018-07-28
130 °æ³² ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ 2018 Post Graduate Asthma School (2ÀÏÂ÷) : 2018-08-26 0 1,080 2018-07-28
129 ¼­¿ï Á¦5ȸ ´ëÇÑ°³¿ø³»°úÀÇ»çȸ °¨¿°º´ ¹× ¹é½Å½ÉÆ÷Áö¿ò : 2018-08-26 0 527 2018-07-28
128 ¼­¿ï Á¦15Â÷ °æ±âµµÀÇ»çȸ Çмú´ëȸ : 2018-08-26 0 1,154 2018-07-28
127 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø °³¿øÀǸ¦ À§ÇÑ °í/½½°üÀý Áúȯ : 2018-08-25 0 565 2018-07-28
126 ºÎ»ê ´ëÇÑÈäºÎ¿Ü°úÇÐȸ 2018 ECMO Symposium and Simulation Workshop : 2018-08-25 0 2,513 2018-07-28
125 ´ëÀü 2018³â ´ëÇÑÅëÁõÇÐȸ Áö¹æ¼øȸ ÃÊÀ½ÆÄ ¹× °æ¸·¿Ü³»½Ã°æWorkshop_ÃÊÀ½ÆÄ¿öÅ©¼ó : 2018-08-25 0 629 2018-07-28
124 ´ëÀü Ãæ³²´ëÇб³º´¿ø Ãæ³²´ëÇб³ ½Å°æ¿Ü°ú ȨĿ¹Ö ½ÉÆ÷Áö¿ò : 2018-08-25 0 902 2018-07-28
123 °æºÏ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Best of ASCO 2018 in Korea : 2018-08-25 0 523 2018-07-28
122 ´ëÀü ´ëÇÑ°»³â±âÇÐȸ 2018 ÇÏ°è¿öÅ©¼¥ : 2018-08-25 0 384 2018-07-28
121 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¼ö¸éÀÇÇÐ:´ÙÇÐÁ¦ Áø·áÀÇ ÀüÇü : 2018-08-25 0 797 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷